ISRAEL AT WAR - DAY 147

search

Painkiller Optalgin allegedly causes bone marrow side-effects in Israeli patients

Health Ministry launches probe into drug whose active ingredient, dipyrone, has been banned in many countries

Illustrative photo of pharmaceutical pills. (Abed Rahim Khatib/Flash90)
Illustrative photo of pharmaceutical pills. (Abed Rahim Khatib/Flash90)

Four patients were hospitalized in Israel in recent months with damage to their bone marrow, a suspected side-effect of taking the painkiller Optalgin.

The drug, maufactured by Teva Pharmaceuticals, contains the active ingredient dipyrone, which is considered dangerous to white blood cells and the bone marrow. In many countries, Dipyrone-based medications are banned or restricted so that they are available only with a prescription. In Israel, however, the drug is available over the counter.

“This is a known complication of Optalgin,” Professor Michael Lishner, head of the Department of Medicine at the Meir Hospital in Kfar Saba, was quoted by Channel 2 News as saying on Thursday. “This medicine was prohibited in the United States many years ago. According to the literature, the mortality rate in patients who used Optalgin and suffered similar symptoms were up to 10%.”

A Health Ministry probe was underway, with findings that are reportedly to be made public by next week. One possible outcome could be a decision to ban the marketing of Optalgin in Israel, or make it a prescription-only drug.

A Teva spokesperson said in response: “We regret the cases and will cooperate fully with the health authorities. Details at this stage are unknown to us, but the data collected over the years indicates this side effect is extremely rare, an estimated one in many millions. The efficacy and safety of the product, which has been marketed worldwide for decades, have been tested and continue to be tested by the ministry.”

read more:
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.